Observational retrospective single‐centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation

Daptomycin‐induced creatinine phosphokinase (CPK) elevation is reported to be associated with its trough level (Ctrough; breakpoint of 24.3 μg/mL). However, even with high‐dose treatment (ie, > 8 mg/kg), the safety of daptomycin treatment is widely demonstrated with low or no significant incidence of CPK elevation or other adverse effects, despite the possibility of Ctrough above 24.3 μg/mL. Therefore, we questioned the clinical significance of Ctrough levels of 24.3 μg/mL. In this study, we retrospectively evaluated the significance of Ctrough in the clinical setting, in addition to completing a retrospective safety assessment of daptomycin utilizing electronic health records.

[1]  Patty W. Wright,et al.  Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Pai,et al.  A Fixed versus Weight‐Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults , 2018, Pharmacotherapy.

[3]  P. Dohmen,et al.  Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data , 2017, Therapeutic advances in infectious disease.

[4]  M. Steed,et al.  Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  E. Durante-Mangoni,et al.  Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. , 2016, International journal of antimicrobial agents.

[6]  R. Seaton,et al.  Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE , 2016, Annals of Clinical Microbiology and Antimicrobials.

[7]  O. Senn,et al.  Therapeutic Drug Monitoring of Daptomycin: A Retrospective Monocentric Analysis , 2013, Therapeutic drug monitoring.

[8]  N. Patel,et al.  Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study , 2014, Infectious Diseases and Therapy.

[9]  Christopher M. Bland,et al.  Musculoskeletal Safety Outcomes of Patients Receiving Daptomycin with HMG-CoA Reductase Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[10]  Melody L. Berg,et al.  Evaluation of Impact of Statin Use on Development of CPK Elevation During Daptomycin Therapy , 2014, The Annals of pharmacotherapy.

[11]  S. Cosgrove,et al.  A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. , 2013, The Journal of antimicrobial chemotherapy.

[12]  Christopher M. Bland,et al.  Safety and Effectiveness of Daptomycin Across a Hospitalized Obese Population: Results of a Multicenter Investigation in the Southeastern United States , 2013, Pharmacotherapy.

[13]  S. Cosgrove,et al.  Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections , 2013, Antimicrobial Agents and Chemotherapy.

[14]  M. Barron,et al.  Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability , 2013, Drug metabolism and drug interactions.

[15]  G. d’Ettorre,et al.  Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[16]  A. Friedrich,et al.  Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. , 2012, International journal of antimicrobial agents.

[17]  Shan-Chwen Chang,et al.  Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections. , 2012, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[18]  K. Welch,et al.  Outcomes of therapy vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients , 2012, Supportive Care in Cancer.

[19]  J. Hernández-Quero,et al.  Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[20]  R. López-Rojas,et al.  Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant Staphylococcus epidermidis , 2011, Antimicrobial Agents and Chemotherapy.

[21]  S. Cosgrove,et al.  High‐Dose Daptomycin for Treatment of Complicated Gram‐Positive Infections: A Large, Multicenter, Retrospective Study , 2011, Pharmacotherapy.

[22]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  K. Welch,et al.  Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients , 2011, Supportive Care in Cancer.

[24]  G. Drusano,et al.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  R. H. Baltz,et al.  Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  C. Urban,et al.  Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  K. Lamp,et al.  Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy , 2009, The Annals of pharmacotherapy.

[28]  W. Craig,et al.  In Vivo Pharmacodynamic Activity of Daptomycin , 2004, Antimicrobial Agents and Chemotherapy.

[29]  Steven D. Brown,et al.  In vitro bactericidal activity of daptomycin against staphylococci. , 2002, The Journal of antimicrobial chemotherapy.

[30]  M. Bergeron,et al.  Protection against gentamicin nephrotoxicity by daptomycin in nephrectomized rats. , 1995, Life sciences.

[31]  C. A. Wood,et al.  Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity , 1989, Antimicrobial Agents and Chemotherapy.

[32]  G. Braemer.  International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.